BIIB news

• Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)

  Seeking Alpha · Oct 16, 2026
• 3 Big Names Enjoying Renewed Analyst Backing

  Schaeffers Research · Oct 12, 2026
• Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Biogen, First Solar, GoDaddy, Hubspot, Palantir Technologies, Robinhood Markets, Snowflake, TeraWulf, T-Mobile US and More

  247 Wallst · Oct 12, 2026
• Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE?

  Fool - Investing News · Oct 11, 2026
• Stock Picks From Seeking Alpha's September 2026 New Analysts

  Seeking Alpha · Oct 7, 2026
• Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says

  Proactive Investors · Oct 6, 2026
• Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

  Zacks Investment Research · Oct 6, 2026
• Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

  GuruFocus · Oct 5, 2026
• Biogen's experimental lupus drug shows benefit against skin symptoms

  Reuters · Oct 2, 2026
• Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

  GlobeNewsWire · Oct 2, 2026
• Biogen (NASDAQ:BIIB) Reaches New 12-Month High – Still a Buy?

  Defense World · Sep 30, 2026
• Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

  Zacks Investment Research · Sep 28, 2026
• 4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

  Zacks Investment Research · Sep 21, 2026
• Mesoblast (NASDAQ:MESO) and Biogen (NASDAQ:BIIB) Head-To-Head Contrast

  Defense World · Sep 18, 2026
• Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

  GlobeNewsWire · Sep 17, 2026
• Corient Private Wealth LP Raises Stock Holdings in Biogen Inc. $BIIB

  Defense World · Sep 17, 2026
• Reviewing Fulcrum Therapeutics (NASDAQ:FULC) & Biogen (NASDAQ:BIIB)

  Defense World · Sep 17, 2026
• LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease

  GlobeNewsWire · Sep 16, 2026
• Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience

  MarketBeat · Sep 15, 2026
• Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  Seeking Alpha · Sep 14, 2026
• Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology

  MarketBeat · Sep 12, 2026
• Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Analysis

  Defense World · Sep 11, 2026
• Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

  Seeking Alpha · Sep 9, 2026
• Lilly Builds Neuroscience into a New Long-Term Growth Driver

  Zacks Investment Research · Sep 8, 2026
• Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t

  GuruFocus · Sep 3, 2026
• Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

  GlobeNewsWire · Sep 3, 2026
• Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

  Business Wire · Sep 3, 2026
• LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China

  GlobeNewsWire · Sep 3, 2026
• Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

  GlobeNewsWire · Sep 1, 2026
• Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease

  GlobeNewsWire · Aug 31, 2026

Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.